India to Saudi Arabia: Enoxaparin Export Trade Route

The India to Saudi Arabia Enoxaparin corridor is one of India's established pharmaceutical export routes, with 289 shipments documented worth a combined $46.1M USD. The route is dominated by GLAND PHARMA LIMITED , which alone accounts for roughly 56% of all export value, reflecting the consolidated nature of India's enoxaparin manufacturing sector.

Across 6 active suppliers, the average shipment value stands at $159.6K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (69%) and air (18%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during January–March, with an average transit time of 15 days port-to-port. The route has recorded an annual growth rate of 15.9%, placing it at rank #8 among India's top enoxaparin export destinations globally.

On the import side, key buyers of Indian enoxaparin in Saudi Arabia include BOSTON ONCOLOGY ARABIA, Boston Oncology Arabia , BOSTON ONCOLOGY ARABIA and 4 others. BOSTON ONCOLOGY ARABIA is the single largest importer with 115 shipments valued at $18.0M USD.

India's enoxaparin exports to Saudi Arabia are driven primarily by a handful of large-scale manufacturers. GLAND PHARMA LIMITED with 136 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 6 active exporters signals a competitive but concentrated market — buyers in Saudi Arabia benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — GLAND PHARMA LIMITED , GLAND PHARMA LIMITED, GLAND PHARMA LTD — together account for 98% of total trade value on this route. The average shipment value of $159.6K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as low molecular weight heparin enoxaparinsodium injection usp 40mg in 0.4ml pre-filled syringe and low molecular weight heparin enoxaparinsodium injection usp, 40mg in 0.4ml pre-filled syringe, suggesting that buyers in Saudi Arabia tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, BOSTON ONCOLOGY ARABIA is the largest importer with 115 shipments worth $18.0M USD — representing 39% of all enoxaparin imports from India on this route. A total of 7 buyers are active on this corridor.